Skip to main content
. 2020 May 26;4(10):2325–2338. doi: 10.1182/bloodadvances.2020001466

Figure 3.

Figure 3.

Long-term efficacy of allo-HSCT after CAR T-cell therapy. (A-B) Of the 102 CR patients, 75 nonrandomly selected patients subsequently were bridged into allo-HSCT (designated the "CAR T bridged into allo-HSCT" group). The remaining 27 patients did not undergo transplantation (designated the "CAR T alone" group). Kaplan-Meier analysis showed that 1-year OS and LFS for patients bridging into allo-HSCT after CAR T-cell therapy were significantly better than those for patients receiving CAR T-cell therapy alone (OS: 79.1% vs 32.0%; P < .0001; hazard ratio [HR], 0.048; 95% CI, 0.016-0.148; LFS: 76.9% vs 11.6%; P < .0001; HR, 35.45; 95% CI, 11.6-108.4).